Isolated Atrial Fibrillation, Inflammation and Efficacy of Radiofrequency Ablation: Preliminary Insights Based on a Single-Center Endomyocardial Biopsy Study.
Roman E BatalovMikhail S KhlyninYulia V RogovskayaSvetlana I SazonovaRoman B TatarskiyNina D AnfinogenovaSergey V PopovPublished in: Journal of clinical medicine (2023)
The aim of the study was to evaluate the inflammatory changes in the myocardium, based on endomyocardial biopsy (EMB) data in patients undergoing radiofrequency ablation (RFA) for idiopathic atrial fibrillation (AF). A total of 67 patients with idiopathic AF were enrolled in the study. Patients underwent the intracardiac examination, RFA of AF, and EMB with histological and immunohistochemical studies. The catheter-treatment effectiveness, and occurrence of early and late recurrences of atrial tachyarrhythmias, were assessed depending on the identified histological changes. Nine patients (13.4%) did not have any histological changes in the myocardium according to EMB. Fibrotic changes were detected in 26 cases (38.8%). Inflammatory changes according to the Dallas criteria were observed in 32 patients (47.8%). The follow-up period for patients averaged 19.3 ± 3.7 months. The effectiveness rates of primary RFA were 88.9% in patients with the intact myocardium, 46.2% in patients with fibrotic changes of varying severity, and 34.4% in patients with the presence of criteria for myocarditis. No early recurrence of arrhythmias was observed in patients with unchanged myocardia. The presence of inflammatory and fibrotic changes in the myocardium increased the rates of early and late arrhythmia recurrences and accordingly halved the effectiveness RFA of AF.
Keyphrases
- atrial fibrillation
- radiofrequency ablation
- end stage renal disease
- ejection fraction
- newly diagnosed
- randomized controlled trial
- patients undergoing
- systematic review
- prognostic factors
- oxidative stress
- systemic sclerosis
- heart failure
- risk assessment
- catheter ablation
- ultrasound guided
- patient reported
- big data
- oral anticoagulants
- deep learning
- electronic health record
- artificial intelligence